# Research Peptide FAQ — GHK-Cu, Semaglutide, Thymosin Alpha-1 — Topical Peptides > Frequently asked questions about three Research Peptide Fundamentals compounds — GHK-Cu, semaglutide, and thymosin alpha-1 — answered from the peer-reviewed literature, with citations. Direct, citation-anchored answers to the questions readers most often bring to GHK-Cu, semaglutide, and thymosin alpha-1. ## What does a GHK-Cu peptide do? GHK-Cu is a copper-binding tripeptide studied for its effects on skin and connective tissue. At very low concentrations it prompts dermal fibroblasts to make more collagen, elastin, and related structural molecules, while the bound copper ion helps cross-link that new tissue and adds mild antioxidant activity [7]. In topical use it is associated with firmer-feeling, smoother skin and, in some formulations, improved hair density on the scalp; injectable or systemic use is unapproved and has no validated human data behind it. ## What is GHK-Cu and how does it work? GHK-Cu is a three-amino-acid peptide (glycine-histidine-lysine) chelated to a copper(II) ion, occurring naturally in the body as collagen turns over. It works by signaling dermal fibroblasts to synthesize more collagen, elastin, and glycosaminoglycans, while the copper component enables an enzyme (lysyl oxidase) to cross-link that new tissue into a stronger structure [6][7]. A 2025 review also documents that GHK modulates a substantial share of measured gene expression toward repair and antioxidant pathways, though this evidence is drawn largely from database analysis rather than direct tissue measurement [2]. ## Is GHK-Cu peptide really anti-aging? The honest answer is: modestly, and mostly in small studies. A review of the clinical literature reports topical GHK-Cu increased collagen production in about 70% of treated subjects, compared with 50% for topical vitamin C and 40% for retinoic acid in the trials it reviewed [1][4]. That is a real, documented signal, but the evidence base behind it is limited in scale — small human trials plus extensive cell-culture and database work — and GHK-Cu's poor natural skin penetration remains an active delivery challenge that newer formulation approaches are still working to solve [1]. It is not a proven cure for aging skin; it is a peptide with a genuine, if modest and incompletely delivered, research signal. ## What is the difference between GHK and GHK-Cu? GHK is the plain tripeptide (glycine-histidine-lysine) on its own; GHK-Cu is that same tripeptide bound to a copper(II) ion. The distinction matters because much of the documented tissue-remodeling activity in the research literature depends on the copper being properly coordinated — the copper-free peptide does not reproduce key effects, such as stimulating certain matrix-remodeling enzymes, in cell studies. When the research or a product describes 'copper peptide' benefits for skin or hair, it is almost always describing GHK-Cu specifically, not the bare GHK sequence. ## What is semaglutide? Semaglutide is a synthetic peptide that acts as a GLP-1 receptor agonist, mimicking glucagon-like peptide-1, a hormone the gut releases after eating. It is FDA-approved for type 2 diabetes, chronic weight management, and reducing cardiovascular risk in adults with established cardiovascular disease and overweight or obesity, and is available as a once-weekly subcutaneous injection or a once-daily oral tablet [10][11]. It is a prescription medicine, not a research-only compound, and this desk describes it here specifically as a contrast case to GHK-Cu's topical delivery story. ## What is semaglutide used for? Clinical uses supported by FDA approval include lowering blood glucose in type 2 diabetes, reducing body weight in chronic weight management, and reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity [10][11]. In dedicated kidney-outcomes research, it also reduced the risk of major kidney-disease events in adults with type 2 diabetes and chronic kidney disease [9]. All uses described here come from published clinical trials, not from this site's own recommendation. ## How does semaglutide work? Semaglutide activates GLP-1 receptors in the pancreas, gut, and brain. In the pancreas, it boosts insulin release only when blood sugar is already elevated, while suppressing glucagon, the hormone that raises blood sugar. In the gut, it slows the rate food leaves the stomach, blunting post-meal glucose spikes. Its resistance to rapid breakdown — engineered through a backbone modification and a fatty-acid side chain that binds blood albumin — gives it a roughly week-long circulating presence, the structural basis for once-weekly dosing [12]. ## How does semaglutide work for weight loss? Semaglutide's weight effect is mostly a brain effect. It reaches appetite-regulating circuits in the hypothalamus and brainstem, activating neurons that signal fullness and quieting neurons that drive hunger-seeking behavior. This reduces overall food intake and, according to many patient reports, the constant background preoccupation with food some describe as 'food noise.' In the STEP 1 trial, this translated into a mean body-weight change of about -14.9% at 68 weeks, versus -2.4% with placebo [11]. ## What is thymosin alpha 1? Thymosin alpha-1 (thymalfasin) is a 28-amino-acid peptide, cleaved in the body from a larger precursor protein, that helps coordinate the immune system's innate and adaptive branches. It is approved as a drug in more than 35 countries, though not in the United States, where it remains investigational [14]. Unlike GHK-Cu, it has no documented topical delivery route; every clinical trial establishing its effects has used subcutaneous injection. ## What does thymosin alpha 1 do? It signals through pattern-recognition receptors (TLR2 and TLR9) on dendritic cells and monocytes, prompting them to mature and present threats to T cells more effectively, which drives T-cell maturation and a pathogen-fighting immune posture. It also engages a regulatory pathway that can generate regulatory T cells, giving it a dual immune-stimulating and immune-balancing character. In one retrospective study, it was associated with restoration of severely depleted T cells and reversal of T-cell exhaustion markers in critically ill COVID-19 patients [15]. ## What is thymosin alpha 1 used for? It has been studied as a treatment for chronic viral hepatitis, where much of its international approval rests, as a supportive immune therapy in severe sepsis, and as a combination-protocol adjuvant alongside chemotherapy and immunotherapy in several cancers [16]. Its sepsis evidence is genuinely mixed: an earlier, smaller trial suggested a mortality benefit [17], while the largest, most rigorous phase 3 trial to date found no significant difference from placebo [13]. ## Is thymosin alpha 1 FDA-approved? No. Thymosin alpha-1 is not approved by the FDA for marketing in the United States, though the synthetic version, thymalfasin, is approved as a drug in more than 35 other countries [14]. In the US it remains investigational, and material sold as 'research-grade' thymosin alpha-1 falls outside the regulated pharmaceutical supply chain, meaning its purity and true identity are not independently guaranteed. --- A literary field guide to how research peptides reach the body — built on citations, not prescriptions, and never a recommended dose.